All In MedTech

Device Trial Radar · NCT05701917

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 6, 2023

Primary completion

Jan 31, 2028

Study completion Jul 31, 2028

Sponsor

Lead sponsor
Inari MedicalNot on our public-company list
Sponsor type
Industry
First posted
Jan 27, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.

Conditions

  • Venous Thromboembolism
  • Deep Venous Thrombosis
  • Post-Thrombotic Syndrome

Interventions

  • ClotTriever SystemDevice

    Mechanical thrombectomy

  • Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.Drug

    Anticoagulants are a group of medications that decrease your blood's ability to clot.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite clinical endpoint constructed as a win ratio, a hierarchy of the following:Time frame: 180 Days (+-14 Days)

Locations

64 sites in 6 countries. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona · Recruiting

63 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.